SYSTEMATIC REVIEWS AND META-ANALYSES



# Indocyanine green fluorescence angiography prevents anastomotic leakage in rectal cancer surgery: a systematic review and meta-analysis

Hua-Yang Pang<sup>1</sup> • Xiao-Long Chen<sup>1</sup> • Xiao-Hai Song<sup>1</sup> • Danil Galiullin<sup>1,2</sup> • Lin-Yong Zhao<sup>1</sup> • Kai Liu<sup>1</sup> • Wei-Han Zhang<sup>1</sup> • Kun Yang<sup>1</sup> • Xin-Zu Chen<sup>1</sup> • Jian-Kun Hu<sup>1</sup>

Received: 6 September 2020 / Accepted: 29 December 2020 © The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature 2021

#### Abstract

**Background** The role of intraoperative use of indocyanine green (ICG) fluorescence angiography (ICGFA) to prevent anastomotic leakage (AL) in rectal cancer surgery remains controversial.

**Methods** The systematic review for studies evaluating ICGFA in patients undergoing rectal cancer surgery in PubMed, Embase, Web of Science, and the Cochrane Library was performed up to April 30, 2020. The primary outcome was the incidence of AL. The analysis was performed using RevMan v5.3 and Stata v12.0 software.

**Results** Eighteen studies comprising 4038 patients were included. In the present meta-analysis, intraoperative use of ICGFA markedly reduced AL rate (OR = 0.33; 95% CI: 0.24–0.45; P < 0.0001;  $I^2 = 0\%$ ) in rectal cancer surgery, which was still significant in surgeries limited to symptomatic AL (OR = 0.44; 95% CI: 0.31–0.64; P < 0.0001;  $I^2 = 22\%$ ). This intervention was also associated with shorter postoperative stays (MD = -1.27; 95% CI: -2.42 to -0.13; P = 0.04;  $I^2 = 60\%$ ). However, reoperation rate (OR = 0.61; 95% CI: 0.34-1.10; P = 0.10;  $I^2 = 6\%$ ), ileus rate (OR = 1.30; 95% CI: 0.60-2.82; P = 0.51;  $I^2 = 56\%$ ), and surgical site infection rate (OR = 1.40; 95% CI: 0.62-3.20; P = 0.42;  $I^2 = 0\%$ ) were not significantly different between the two groups.

**Conclusion** The use of ICGFA was associated with a lower AL rate after rectal cancer resection. However, more multi-center RCTs with large sample size are required to further verify the value of ICGFA in rectal cancer surgery.

Keywords Rectal cancer · Indocyanine green · Fluorescence angiography · Anastomotic leakage · Meta-analysis

# Introduction

Anastomotic leakage (AL) is one of the most devastating complications following rectal cancer surgery, accounting for considerable morbidity and mortality [1–3]. Despite big progress

| PROSPERO registration number: CRD42020156416    |  |
|---|--|
| Hua-Yang Pang and Xiao-Long Chen are co-authors |  |

☑ Jian-Kun Hu hujkwch@126.com in perioperative management has been made in recent years, the reduction of AL rate in rectal cancer surgery still remains unsatisfactory [4, 5]. Due to the differences in AL's definition and classification in present published literatures, it has been reported that the AL rate after rectal cancer surgery ranged from 6 to 19% [6–8].

So far, multiple conditions have been identified as risk factors of AL, like age, male gender, smoking, diabetes, previous chemoradiotherapy, intraoperative complication, anastomotic tension, and hypoperfusion [4, 9]. Of those, insufficient blood perfusion of anastomotic site plays an important role in the pathogenesis of AL [9].

To prevent AL, several clinical signs such as bowel serosal color, temperature and vascular pulsation, as well as some clinical adjuncts including Doppler ultrasound and tissue pulse oximetry have been used to assess bowel perfusion [10]. Nevertheless, none of them is satisfactory in clinical application, due to their subjective nature and the limitation

<sup>&</sup>lt;sup>1</sup> Department of Gastrointestinal Surgery and Laboratory of Gastric Cancer, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, No 37 Guo Xue Xiang Street, Chengdu 610041, Sichuan Province, China

<sup>&</sup>lt;sup>2</sup> Central Research Laboratory, Bashkir State Medical University, Ufa, Russia

of feasibility and reproducibility. In recent years, indocyanine green (ICG) fluorescence angiography (ICGFA) is emerging as a relatively new technique to assess bowel perfusion [11]. ICG is a kind of non-toxic tricarbocyanine iodide dye which can be safely injected intravenously and quickly binds to blood lipoproteins [12]. Under near-infrared light (excitation wavelength of 750–800 nm), ICG could emit fluorescent light at 830 nm or more, which allows surgeons to directly visualize the microperfusion of intestine in real time and avoid insufficient perfusion of the anastomosis site [13]. Recently, several meta-analyses [14–16] have demonstrated that ICGFA can help reduce AL rate in rectal cancer surgery, but most of them were not convincing due to the limited number of included studies and small number of patients.

Herein, we updated this meta-analysis to evaluate whether this technique could decrease AL rate in patients undergoing rectal cancer resection based on recently published studies.

# Materials and methods

This systematic review and meta-analysis was performed in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [17] (Fig. 1). The study protocol was registered in PROSPERO, and the registration number is CRD42020156416.

#### Search strategy

A comprehensive and systematic search of electronic databases including PubMed, Embase, Web of Science, and the Cochrane Library was undertaken to identify relevant studies published up to April 30, 2020. The following combination of keywords was searched to identify potential articles: ["indocyanine green" OR "ICG" OR "fluorescence angiography"] AND ["colorectal surgery" OR "colorectal cancer" OR "rectal surgery" OR "rectal cancer"]. No language or publication date restrictions were applied in the search strategy. Meanwhile, the bibliography of the studies and previously published reviews were also searched for additional reports. The search was conducted independently by two authors (HY-P and XL-C).

#### Study selection

Eligible studies met the following criteria: (1) patients undergoing rectal cancer surgery; (2) with reported outcomes comparing AL incidence between the ICGFA and the control group; (3) any sample size; and (4) in the case of duplicate publications, only the most complete study was included. The exclusion criteria are (1) studies published as reviews, case reports, comments, and letters; (2) data was inadequate for meta-analysis or could not be acquired form the author; and (3) articles without technical description of ICGFA assessing



anastomosis perfusion. All discordant articles were adjudicated by a third reviewer (JK-H).

#### Data extraction and quality assessment

According to the inclusion and exclusion criteria, two authors (HY-P and XL-C) independently selected the studies and extracted the data. The following information from each article was collected: the first author, year of publication, country of the study, study design, enrollment period, sample size, patient characteristics like age and gender, type of surgery, ICG dosage, the time of ICGFA use, imaging system used, change of surgical plan in the ICGFA group, and the definition and follow-up time of AL.

The primary outcome was AL, identified clinically, radiologically, and endoscopically. The secondary outcomes were surgical site infection (which included wound infection and abdominal infection), ileus (which was defined as prolonged gastrointestinal recovery after surgery leading to abdominal distension, vomiting, oral intolerance, and delayed elimination [18]), reoperation (which caused by any severe postoperative complications), and postoperative stays.

We assessed the quality of studies independently after reading the full text of each study. The Cochrane Collaboration Risk of Bias Tool was used to evaluate the quality of involved RCTs [19], and the Newcastle-Ottawa Scale (NOS) was employed to evaluate the quality of observational studies [20].

## **Statistical analysis**

Dichotomous and continuous variables were evaluated using odds ratio (OR) and mean difference (MD) with their 95% confidence intervals (CIs), respectively. For studies that only reported median with range or interquartile range, data were converted into mean with standard deviation (SD) following the method reported by McGrath et al [21] Heterogeneity among studies was assessed using  $\chi^2$  and  $I^2$  statistics. *P* value < 0.05 and  $I^2 > 50\%$  indicate significant heterogeneity. In this case, a random-effect model was used; otherwise, a fixed-effect model was performed. Publication bias was evaluated using funnel plot and Begg's test. A *P* value < 0.05 was considered significant. All statistical analyses were performed using Review Manager Software, version 5.3 (Cochrane, London, UK) and Stata, version 12.0 (Stata Corp, College Station, TX).

### Level of evidence

The quality of evidence of each outcome was assessed using GRADE approach [22]. Briefly, each endpoint was given a score, which ranges from very low to high, on the basis of following domains: risk of bias, inconsistency, indirection, and imprecision (Table 3).

## Results

The literature search identified a total of 1692 papers. After reading the titles or abstracts, 1209 studies were excluded because they did not meet the inclusion criteria. Through screening the full text of the 89 remaining articles, 22 comparative studies [23–44] which contained rectal cancer surgery were possible to extract data. For studies with mixed data [23, 27, 28, 34, 41, 44, 45], the authors were contacted for separate data related to rectal cancer surgery, and 3 of the authors [23, 27, 44] provided data. Finally, 18 studies [23–27, 29–33, 36–40, 42–44] were included in the present study.

#### Characteristics of studies and quality assessment

The summarized information of these studies was presented in Tables 1 and 2. A total of 4038 patients from 8 countries were included into this study. The sample size ranged from 36 to 844. Among these studies, there were 2 RCTs [23, 27], 3 prospective studies [38, 40, 44], and 13 retrospective studies [24-26, 29-33, 36, 37, 39, 42-44], which were published from 2013 to 2020. With respect to the ICGFA assessing anastomosis perfusion, the doses of ICG and imaging systems used were variant, and the change of surgical plan ranged from 1.1 to 28.7% in these studies. In addition, the definition and follow-up time of AL were different in these studies. The details of quality assessment of included studies were shown in supplementary file (Table S1 and S2). Both RCTs had high risk of bias in at least one assessed category, and the observational studies were ranged from 6 to 8 assessed by NOS, Table 3.

#### **Outcome assessment**

#### Primary outcome: anastomotic leakage

The meta-analysis of 18 studies [23-27, 29-33, 36-44] included 4038 patients undergoing rectal cancer surgery, comprising 1495 in the ICGFA group and 2543 in the control group. The overall AL rate was 8.4% (3.9% in the ICGFA group and 11.0% in the control group). The pooled analysis demonstrated that the use of ICGFA could significantly decrease the incidence of AL after rectal cancer surgery (OR: 0.33; 95% CI: 0.24–0.45; P < 0.0001;  $I^2 = 0\%$ ) (Fig. 2a). Additionally, when surgeries limited to symptomatic AL (Clavien-Dindo [46] grade  $\geq$  II) [23–27, 29, 31, 32, 40, 42-44], the use of ICGFA showed a positive effect on reducing AL rate (OR = 0.44; 95% CI: 0.31–0.64; P < 0.0001;  $I^2$  = 22%) (Fig. 2b). Then, we also conducted subgroup analyses based on study design (RCT vs. non-RCT), country (western vs. eastern), sample size ( $\geq 100$  vs. < 100), the time of ICGFA use (before anastomosis vs. both before and after anastomosis), and the follow-up duration of AL (within 30 days, beyond

| Reference                  | Country     | Study interval                 | Study<br>design | Sample<br>size | Number of<br>patients (I:C) | Age (I:C), (mean<br>or median), year | Sex (I:C),<br>(male, %) | BMI (I:C), (mean<br>or median), Kg/m <sup>2</sup> | Neoadjuvant<br>chemoradiotherapy<br>(I:C), (%) | Surgery<br>procedure |
|----------------------------|-------------|--------------------------------|-----------------|----------------|-----------------------------|--------------------------------------|-------------------------|---|--|----------------------|
| Alekseev, 2020 [23]        | Russia      | 2017-2019                      | S; RCT          | 325            | 166:159                     | NA                                   | NA                      | NA  | NA   | AR                   |
| Bonadio, 2020 [24]         | Italy       | I: 2015–2017;<br>C: 2014–2015  | S; R            | 66             | 33:33                       | 71.9/69.0                            | 63.6/45.5               | 25.6/25.7   | 48.5/42.4                                      | AR                   |
| Boni, 2016 [ <b>25</b> ]   | Italy       | I:2014–2015;<br>C:2012–2013    | S; R            | 80             | 42:38                       | 69.0/67.0                            | 66.7/57.9               | 27.0/29.0   | 78.0/60.0                                      | LAR                  |
| Brescia, 2018 [26]         | Italy       | 2014-2017                      | S; R            | 52             | 21:31                       | NA                                   | NA                      | NA  | NA   | AR                   |
| De Nardi, 2019 [27]        | Italy       | 2016-2017                      | S; RCT          | 108            | 56:53                       | NA                                   | NA                      | NA  | NA   | LAR                  |
| Hasegawa, 2020 [29]        | Japan       | I:2016–2017;<br>C: 2007–2016   | S; R            | 844            | 141:703                     | 63.0/62.0                            | 70.2/64.0               | 22.3/22.9   | 18.4/11.0                                      | LAR; ISR             |
| Impellizzeri, 2020 [30]    | Italy       | I:2017–2019<br>C:2014–2016     | S; R            | 73             | 37:36                       | NA                                   | NA                      | NA  | NA   | LAR                  |
| Ishii, 2019 [ <b>31</b> ]  | Japan       | I:2017–2018;<br>C:2014–2018    | S; R            | 220            | 116:104                     | 64.0/65.0                            | 59.5/58.7               | 22.3/22.8   | 33.6/22.1                                      | HAR; LAR; ISR        |
| Jafari, 2013 [ <b>32</b> ] | USA         | 2011-2012                      | S; R            | 38             | 16:22                       | 58.0/63.0                            | 75.0/72.7               | 27.0/27.0   | 63.0/68.0                                      | LAR                  |
| Kim, 2017 [33]             | Korea       | I:2013–2016;<br>C:2010–2016    | S; R            | 657            | 310:347                     | 58.0/57.0                            | 58.7/62.2               | 23.9/23.9   | 31.0/30.0                                      | LAR; ISR             |
| Mizrahi, 2018 [36]         | USA         | I:2015–2016;<br>C:2013–2015    | S; R            | 60             | 30:30                       | 58.0/58.0                            | 53.3/60.0               | 25.9/27.2   | 56.7/46.7                                      | L-LAR                |
| Otero-Piñeiro, 2020 [37]   | Spain       | I:2016–2018;<br>C:2011–2016    | S; R            | 284            | 80:204                      | 68.0/66.6                            | 63.8/60.3               | 26.1/25.4   | 46.2/55.7                                      | HAR; LAR             |
| Ris, 2018 [38]             | Switzerland | 2013-2016                      | M; P            | 455            | 90:365                      | NA                                   | NA                      | NA  | NA   | LAR                  |
| Shapera, 2019 [39]         | USA         | 2012-2018                      | S; R            | 36             | 22:14                       | NA                                   | NA                      | NA  | NA   | LAR                  |
| Skrovina, 2019 [40]        | Czech       | I:2015–2017;<br>C: before 2015 | S; P            | 100            | 50:50                       | 62.4/65.0                            | 68.0/58.0               | 27.0/27.0   | 68.0/74.0                                      | LAR                  |
| Wada, 2018 [42]            | Japan       | I:2013–2016;<br>C:2009–2016    | S; R            | 149            | 48:101                      | 66.0/67.0                            | 64.6/69.3               | 22.5/21.4   | 10.4/22.8                                      | LAR                  |
| Watanabe, 2019 [43]        | Japan       | 2014-2017                      | M; R            | 422            | 211:211                     | 66.0/66.0                            | 60.7/62.1               | 22.3/22.4   | 19.9/23.2                                      | LAR                  |
| Wojcik, 2020 [44]          | France      | 2017-2018                      | S; P            | 68             | 26:42                       | NA                                   | NA                      | NA  | NA   | AR                   |

Table 1Basic information of included studies

| Table 2         The detailed in | nformation of | included studies                              |                                  |  |  |                                  |                                   |
|---------------------------------|---------------|---|----------------------------------|--|--|----------------------------------|-----------------------------------|
| Reference                       | ICG dose      | Time of ICG use (before or after anastomosis) | Imaging system                   | Change of surgical plan in ICG group (%) | Definition of AL   | Clavien-<br>Dindo<br>grade of AL | Follow-up of AL occurrence (days) |
| Alekseev, 2020 [23]             | 0.2 mg/kg     | Before  | SPIES system                     | NA                                       | Clinical, endoscopic, radiological                         | ≥I                               | 30                                |
| Bonadio, 2020 [24]              | 0.2 mg/kg     | Before and after                              | SPIES system                     | 18.2                                     | Clinical; radiological                                     | ≥I                               | 30                                |
| Boni, 2016 [ <b>25</b> ]        | 0.2 mg/kg     | Before and after                              | SPIES system                     | 4.7                                      | Clinical; radiological                                     | ≥I                               | NA                                |
| Brescia, 2018 [26]              | 0.25 mg/kg    | Before and after                              | SPIES system                     | 4.8                                      | Radiological   | ≥II                              | NA                                |
| De Nardi, 2019 [27]             | 0.3 mg/kg     | Before and after                              | SPIES system                     | 11.0                                     | Clinical, laboratory, radiological,                        |                                  | 30                                |
|                                 |               | <u> </u>                                      |                                  |  | endoscopy, or surgery                                      | ш                                | 20                                |
| nasegawa, 2020 [29]             | дш 0.с        | Delore  | SFIES System                     | 17.0                                     | Cunicat; pnysicat examination;<br>endoscopic; radiological | II -                             | 00                                |
| Impellizzeri, 2020 [30]         | 25 mg         | Before and after                              | SPIES system                     | 4.0                                      | NA   | ≥I                               | 60                                |
| Ishii, 2019 [ <b>3</b> 1]       | 5.0 mg        | Before  | 1588/1688 AIM laparoscope system | 5.2                                      | Clinical; endoscopic; radiological                         | I                                | 30                                |
| Jafari, 2013 [ <b>32</b> ]      | 6-8 mg        | Before  | Firefly system                   | 19.0                                     | Endoscopic; radiological                                   | ≥II                              | 60                                |
| Kim, 2017 [33]                  | 10 mg         | Before $\pm$ after                            | Firefly system                   | NA                                       | Endoscopic; radiological                                   | I<∣                              | 06                                |
| Mizrahi, 2018 [36]              | 0.1 - 0.3     | Before and after                              | PINPOINT System                  | 13.3                                     | Physical examination;                                      | ≥I                               | 60                                |
|                                 | mg/kg         |   |                                  |  | clinical; endoscopic; radiological                         |                                  |                                   |
| Otero-Piñeiro, 2020 [37]        | 2.5 mg/ml     | Before and after                              | PINPOINT System                  | 28.7                                     | Clinical; physical<br>examination; radiological            | I                                | 30                                |
| Ris, 2018 [38]                  | 7.5 mg        | Before and after                              | PINPOINT System                  | 1.1                                      | NA   | ≥I                               | NA                                |
| Shapera, 2019 [39]              | 25 mg         | Before and after                              | Firefly system                   | NA                                       | NA   | ≥I                               | 30                                |
| Skrovina, 2019 [40]             | 0.2 mg/kg     | Before  | SPIES and Firefly system         | 12.0                                     | radiological   | ≥I                               | 30                                |
| Wada, 2018 [42]                 | 5 mg          | Before  | PDE-neo system                   | 27.1                                     | Radiological; physical<br>examination: endoscopic          | ≥II                              | NA                                |
| Watanabe, 2019 [43]             | 0.25 mg/kg    | Before  | SPIES system                     | 5.7                                      | NA   | ≥II                              | 30                                |
| Wojcik, 2020 [44]               | 0.1 mg/kg     | Before  | FLUOBEAM and PINPOINT system     | 10.9                                     | Clinical, radiological                                     |                                  | 30                                |
| I=ICG group; C=Contro           | l group; AL = | Anastomotic leakage; NA =                     | .Not available                   |  |  |                                  |                                   |

Langenbecks Arch Surg

#### Table 3Summary of findings

| Outcomes assessment     | Included studies | ICGGA (n) | Control ( <i>n</i> ) | Test of<br>heterogeneity |         | Meta-analys | Quality of evidence<br>(GRADE) |          |                             |
|-------------------------|------------------|-----------|----------------------|--------------------------|---------|-------------|--------------------------------|----------|-----------------------------|
|                         |                  |           |                      | $I^{2}(\%)$              | P value | OR or MD    | 95% CI                         | P value  |                             |
| Anastomotic leakage     | 18               | 1495      | 2543                 | 0                        | 0.71    | 0.33        | 0.24-0.45                      | < 0.0001 | Low <sup>a, f</sup>         |
| Ileus                   | 6                | 526       | 742                  | 56                       | 0.04    | 1.30        | 0.60-2.82                      | 0.51     | Very low <sup>a, b, d</sup> |
| Surgical site infection | 6                | 427       | 606                  | 0                        | 0.72    | 1.40        | 0.62-3.20                      | 0.42     | Very low <sup>a, d</sup>    |
| Reoperation             | 5                | 515       | 634                  | 6                        | 0.37    | 0.61        | 0.34-1.10                      | 0.10     | Very low <sup>a, d</sup>    |
| Postoperative stays     | 5                | 549       | 672                  | 60                       | 0.04    | -3.00       | -5.46 to -0.13                 | 0.03     | Very low <sup>a, b, d</sup> |

Downgrade quality of evidence: <sup>a</sup>risk of bias, <sup>b</sup> inconsistency; <sup>c</sup> indirectness; <sup>d</sup> imprecision. Upgrade quality of evidence: <sup>f</sup> large effect; <sup>g</sup> plausible confounding would change the effect; <sup>h</sup> dose-response gradient. *OR* odds ratio, *MD* mean difference

30 days, and unknown). All of these results were not significantly different by these stratifications with P = 0.27, 0.95, 0.33, 0.27, and 0.26, respectively (Table 4 and Fig. S1–5).

### Secondary outcomes

**Other postoperative complications** The incidence of ileus was reported in 6 studies [25, 32, 33, 36, 37, 42] (Fig. 3a). The ileus rates were 7.2% in the ICGFA group and 7.3% in the control group. The pooled OR was 1.30 (95% CI: 0.60–2.82; P = 0.51;  $I^2 = 56\%$ ).

Six studies [25, 32, 36, 37, 42, 43] reported that the surgical site infection rates were 2.8% in the ICGFA group and 1.8%

in the control group. The pooled OR was 1.40 (95% CI: 0.62– 3.20; P = 0.42;  $l^2 = 0\%$ ) (Fig. 3b).

**Reoperation** A total of 5 studies [23, 25, 32, 37, 42, 43] reported on reoperation (Fig. 4), of which, the reoperation rate was 3.3% in the ICGFA group and 6.5% in the control group. The pooled OR was 0.61 (95% CI: 0.34–1.10; P = 0.10;  $I^2 = 6\%$ ).

**Postoperative stays** Five studies [23, 25, 37, 40, 43] provided data on postoperative stays (Fig. 5). The pooled analysis suggested that the use of ICGFA was significantly associated with shorter postoperative stays (MD = -1.27 (95% CI: -2.42 to -0.13; P = 0.04;  $I^2 = 60\%$ )).

| Subgroup                     | Included studies | ICGGA (n) | Control ( <i>n</i> ) | Test of he         | eterogeneity | Meta-analysis |           |          |  |
|------------------------------|------------------|-----------|----------------------|--------------------|--------------|---------------|-----------|----------|--|
|                              |                  |           |                      | I <sup>2</sup> (%) | P value      | OR            | 95% CI    | P value  |  |
| Total AL                     | 18               | 1495      | 2543                 | 0                  | 0.71         | 0.33          | 0.24-0.45 | < 0.0001 |  |
| Symptomatic AL               | 12               | 926       | 1547                 | 22                 | 0.23         | 0.44          | 0.31-0.64 | < 0.0001 |  |
| Study design                 |                  |           |                      |                    |              |               |           |          |  |
| RCT                          | 2                | 222       | 212                  | 0                  | 0.82         | 0.44          | 0.25-0.80 | 0.007    |  |
| Non-RCT                      | 16               | 1273      | 2331                 | 0                  | 0.63         | 0.30          | 0.24-0.43 | < 0.0001 |  |
| Country                      |                  |           |                      |                    |              |               |           |          |  |
| Eastern                      | 5                | 826       | 1466                 | 58                 | 0.05         | 0.36          | 0.17-0.77 | 0.008    |  |
| Western                      | 13               | 669       | 1077                 | 0                  | 0.99         | 0.35          | 0.23-0.53 | < 0.0001 |  |
| Sample size                  |                  |           |                      |                    |              |               |           |          |  |
| $\geq 100$                   | 10               | 1268      | 2297                 | 19                 | 0.27         | 0.35          | 0.25-0.48 | < 0.0001 |  |
| <100                         | 8                | 227       | 246                  | 0                  | 0.71         | 0.22          | 0.09-0.54 | 0.001    |  |
| The time of ICG performance  |                  |           |                      |                    |              |               |           |          |  |
| Before anastomosis           | 8                | 774       | 1392                 | 4                  | 0.40         | 0.39          | 0.27-0.56 | < 0.0001 |  |
| Before and after anastomosis | 9                | 411       | 804                  | 0                  | 0.98         | 0.26          | 0.14-0.49 | < 0.0001 |  |
| Follow-up duration           |                  |           |                      |                    |              |               |           |          |  |
| Within 30 days               | 10               | 901       | 1573                 | 0                  | 0.91         | 0.34          | 0.24-0.48 | < 0.0001 |  |
| Beyond 30 days               | 4                | 393       | 435                  | 0                  | 0.93         | 0.15          | 0.05-0.45 | 0.0006   |  |
| Unknown                      | 4                | 201       | 535                  | 46                 | 0.14         | 0.46          | 0.22–0.96 | 0.04     |  |

 Table 4
 Subgroup analyses of the efficacy ICGFA versus no ICGFA in preventing AL in rectal cancer patients



Fig. 2 Forest plot evaluating (a) overall anastomotic leakage and (b) symptomatic leakage between the ICGFA and the control group in rectal cancer patients

# **Publication bias**

The funnel plot and Begg's test were used to assess the potential publication bias in the meta-analysis of the primary outcome. As shown in supplementary file (Fig. S6), the funnel plot was almost symmetric, and the P value of Begg's test was 0.202, which indicated that there was a low risk of publication bias in this study.

# Discussion

This is the largest meta-analysis ever published to study the influence of ICGFA on AL in patients with rectal cancer surgery. Our pooled analysis of 4038 patients demonstrated that the intraoperative use of ICGFA was associated with a lower AL rate after rectal cancer resection. In addition, this intervention was associated with shorter postoperative stays, which might be related to the reduction in AL.

The negative effects of AL in rectal cancer surgery are undeniable. In medical cost, Ashraf et al. [47] reported the average cost was £17,220 in rectal cancer surgery patients who suffered from AL, which was significantly higher than those without (£ 6319). Besides, many studies have identified that AL was an independent risk factor for poor longterm survival in rectal cancer [48, 49]. Thus, it is crucial to prevent AL after rectal cancer resection. As mentioned above, a lot of patient-related (male gender, age, and diabetes), tumor-related (neoadjuvant chemoradiotherapy and low anastomosis), and surgery-related parameters (anastomotic tension and hypoperfusion) have been identified as risk factors for the incidence of AL [4]. However, among these risk factors, anastomotic perfusion represents one of the few modifiable variables.



Fig. 3 Forest plot evaluating (a) ileus and (b) surgical site infection between the ICGFA and the control group in rectal cancer patients

In recent years, there has been ongoing interest on the use of ICGFA to assess anastomotic perfusion due to its relative ease of use, low cost, and satisfactory safety [33, 38]. Several recently published meta-analyses [14–16, 18] have demonstrated that the risk of developing AL after colorectal surgery was decreased significantly in patients with ICGFA, which was in line with our result. However, most of them were not convincing due to the limited number of included observational studies. Compared to these studies, the strength of our metaanalysis is the thorough inclusion of all applicable RCTs, prospective, and retrospective studies, which allowed us to analyze a larger sample size than previous meta-analyses. Besides, our study is more specific in the interventions in that we included rectal cancer patients only, which is a population that is likely to benefit the most from the interventions because of the high incidence of AL in rectal cancer resection compared to colon cancer surgery.

By performing subgroup analyses, we are able to explain the study heterogeneity. First, by limiting our analysis to patients who had a symptomatic AL, we found that the use of ICGFA still showed a superior effect on the reduction of clinically important AL, which further demonstrated the clinical value of this new technique. Second, with including two recently published RCTs, we could find that there was no subgroup difference based on study design (RCT vs. non-RCT), which provided us a more definitive proof of the benefit of ICGFA on AL reduction. Third, we also explored whether the time of ICGFA performance (before anastomosis vs. both before and after anastomosis) could affect the primary outcome. We found that assessing bowel perfusion both before and after anastomosis (OR = 0.26) seemed more effective than merely doing this before anastomosis (OR = 0.39) on the reduction of AL, even there was no significant subgroup difference existed. Therefore, applying ICGFA both before and after anastomosis to evaluate bowel perfusion may be a better choice to prevent AL in future clinical practice. In addition, we further performed subgroup analyses based on country (Western vs. Eastern), sample size ( $\geq 100$  vs. < 100), and the follow-up duration (within 30 days vs. beyond 30 days vs. unknown) and found that there were no significant differences



Fig. 4 Forest plot evaluating reoperation between the ICGFA and the control group in rectal cancer patients



Fig. 5 Forest plot evaluating postoperative stays between the ICGFA and the control group in rectal cancer patients

based on these stratifications. Therefore, considering the low heterogeneity and low risk of publication bias, the intraoperative use of ICGFA may be a promising tool to prevent AL in rectal cancer surgery.

Currently, accumulating studies [50–52] focusing on quantitative fluorescence angiography has provided us a more thorough understanding of how ICGFA can facilitate the reduction of AL rate. A systematic review [53] of 13 studies by Lütken et al. found that the leakage of anastomotic site was closely associated with the inflow parameters such as time-topeak, slope, and  $t_{1/2}$  max, which scientifically demonstrated that the effect observed in our meta-analysis is realized at the anastomotic site. Quantifying the ICGFA generates objective and precise perfusion values, which may help surgeons decide whether the change of surgical plan is needed and eliminate the subjective limitations of qualitative (visual) method [54].

There were several limitations in the present study. First, the predominately included studies were observational studies. The insufficiency of RCTs may lead to increase the risk of bias, and more high-quality RCTs are required to provide more credible evidence on this issue. Second, the administrated dosage of ICG and imaging systems among these studies were different, which might also cause bias due to the difference in signal detectability. Additionally, the definition of AL was inconsistent in these studies (Table 2). Skrovina et al. [40] diagnosed AL just by radiological finding, while Kim et al. [33] identified AL based on not only radiological examination but also physical and endoscopic examinations. These variations might bring heterogeneity to the outcome analysis.

In conclusion, this systematic review and meta-analysis offered encouraging evidence that the intraoperative use of ICGFA was associated with an appreciable reduction in AL. However, taking in account the abovementioned limitations and low level of evidence of the comparisons, more multicenter RCTs with large sample size are required to verify the result of our study.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00423-020-02077-6.

Authors' contributions Study conception and design: Hua-Yang Pang, Xiao-Long Chen, and Jian-Kun Hu. Acquisition of data: Hua-Yang Pang, Xiao-Long Chen, Xiao-Hai Song, Danil Galiullin, and Lin-Yong Zhao. Analysis and interpretation of data: Hua-Yang Pang, Xiao-Long Chen, Xiao-Hai Song, and Kai Liu. Drafting of manuscript: Hua-Yang Pang and Xiao-Long Chen. Critical revision of manuscript: Hua-Yang Pang, Xiao-Long Chen, Xiao-Hai Song, Wei-Han Zhang, Kun Yang, and Xin-Zu Chen. Final approval of the version to be published: Jian-kun Hu.

**Funding** This research was supported by (1) 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University (ZY2017304); (2) Sichuan Science and Technology Program (No.2019YFS0255); and (3) Ten Thousand Talent Program of Sichuan Province (No.101).

**Data availability** All data generated or analyzed during this study are included in the published article.

#### **Compliance with ethical standards**

**Conflict of interest** The authors declare that they have no conflict of interests.

**Ethical approval** Considering the nature of this study, ethical approval was not required.

**Human and animal rights** This study is a systematic review with metaanalysis of outcomes which does not include research directly involving human or animal participation.

**Informed consent** Considering the nature of this study, informed consent was not required.

# References

- Fukada M, Matsuhashi N, Takahashi T, Imai H, Tanaka Y, Yamaguchi K, Yoshida K (2019) Risk and early predictive factors of anastomotic leakage in laparoscopic low anterior resection for rectal cancer. World J Surg Oncol 17:178
- Hoshino N, Hida K, Sakai Y, Osada S, Idani H, Sato T, Takii Y, Bando H, Shiomi A, Saito N (2018) Nomogram for predicting anastomotic leakage after low anterior resection for rectal cancer. Int J Color Dis 33:411–418
- Kang CY, Halabi WJ, Chaudhry OO, Nguyen V, Pigazzi A, Carmichael JC, Mills S, Stamos MJ (2013) Risk factors for anastomotic leakage after anterior resection for rectal cancer. JAMA Surg 148:65–71
- Chadi SA, Fingerhut A, Berho M, DeMeester SR, Fleshman JW, Hyman NH, Margolin DA, Martz JE, McLemore EC, Molena D, Newman MI, Rafferty JF, Safar B, Senagore AJ, Zmora O, Wexner SD (2016) Emerging trends in the etiology, prevention, and treatment of gastrointestinal anastomotic leakage. J Gastrointest Surg 20:2035–2051

- Vallance A, Wexner S, Berho M, Cahill R, Coleman M, Haboubi N, Heald RJ, Kennedy RH, Moran B, Mortensen N, Motson RW, Novell R, O'Connell PR, Ris F, Rockall T, Senapati A, Windsor A, Jayne DG (2017) A collaborative review of the current concepts and challenges of anastomotic leaks in colorectal surgery. Color Dis 19:O1–o12
- Blanco-Colino R, Espin-Basany E (2018) Intraoperative use of ICG fluorescence imaging to reduce the risk of anastomotic leakage in colorectal surgery: a systematic review and meta-analysis. Tech Coloproctol 22:15–23
- Ellebaek MB, Rahr HB, Boye S et al (2019) Detection of early anastomotic leakage by intraperitoneal microdialysis after low anterior resection for rectal cancer: a prospective cohort study. Color Dis 21:1387–1396
- Pommergaard HC, Gessler B, Burcharth J, Angenete E, Haglind E, Rosenberg J (2014) Preoperative risk factors for anastomotic leakage after resection for colorectal cancer: a systematic review and meta-analysis. Color Dis 16:662–671
- Vignali A, Gianotti L, Braga M, Radaelli G, Malvezzi L, Carlo VD (2000) Altered microperfusion at the rectal stump is predictive for rectal anastomotic leak. Dis Colon Rectum 43:76–82
- Hirst NA, Tiernan JP, Millner PA, Jayne DG (2014) Systematic review of methods to predict and detect anastomotic leakage in colorectal surgery. Color Dis 16:95–109
- Degett TH, Andersen HS, Gögenur I (2016) Indocyanine green fluorescence angiography for intraoperative assessment of gastrointestinal anastomotic perfusion: a systematic review of clinical trials. Langenbeck's Arch Surg 401:767–775
- Keller DS, Ishizawa T, Cohen R, Chand M (2017) Indocyanine green fluorescence imaging in colorectal surgery: overview, applications, and future directions. Lancet Gastroenterol Hepatol 2:757– 766
- Alander JT, Kaartinen I, Laakso A et al (2012) A review of indocyanine green fluorescent imaging in surgery. Int J Biomed Imaging 2012:940585
- 14. Song M, Liu J, Xia D, Yao H, Tian G, Chen X, Liu Y, Jiang Y, Li Z (2020) Assessment of intraoperative use of indocyanine green fluorescence imaging on the incidence of anastomotic leakage after rectal cancer surgery: a PRISMA-compliant systematic review and meta-analysis. Tech Coloproctol
- 15. Liu D, Liang L, Liu L, Zhu Z (2020) Does intraoperative indocyanine green fluorescence angiography decrease the incidence of anastomotic leakage in colorectal surgery? A systematic review and meta-analysis. Int J Color Dis
- Shen Y, Yang T, Yang J, Meng W, Wang Z (2020) Intraoperative indocyanine green fluorescence angiography to prevent anastomotic leak after low anterior resection for rectal cancer: a meta-analysis. ANZ J Surg 90:2193–2200
- 17. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62:e1–e34
- Lin J, Zheng B, Lin S, Chen Z, Chen S (2020) The efficacy of intraoperative ICG fluorescence angiography on anastomotic leak after resection for colorectal cancer: a meta-analysis. Int J Color Dis
- Cumpston M, Li T, Page MJ et al (2019) Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev 10:Ed000142
- Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in metaanalyses. Eur J Epidemiol 25:603–605
- 21. McGrath S, Zhao X, Steele R et al (2020) Estimating the sample mean and standard deviation from commonly reported quantiles in meta-analysis. Stat Methods Med Res 962280219889080

- 22. Atkins D, Best D, Briss PA et al (2004) Grading quality of evidence and strength of recommendations. Bmj 328:1490
- Alekseev M, Rybakov E, Shelygin Y, Chernyshov S, Zarodnyuk I (2020) A study investigating the perfusion of colorectal anastomoses using fluorescence angiography: results of the FLAG randomized trial. Color Dis 22:1147–1153
- Bonadio L, Iacuzzo C, Cosola D, Cipolat Mis T, Giudici F, Casagranda B, Biloslavo A, de Manzini N (2020) Indocyanine green-enhanced fluorangiography (ICGf) in laparoscopic extraperitoneal rectal cancer resection. Updat Surg 72:477–482
- 25. Boni L, Fingerhut A, Marzorati A, Rausei S, Dionigi G, Cassinotti E (2017) Indocyanine green fluorescence angiography during laparoscopic low anterior resection: results of a case-matched study. Surg Endosc 31:1836–1840
- Brescia A, Pezzatini M, Romeo G, Cinquepalmi M, Pindozzi F, Dall'Oglio A, Gasparrini M, Lazar F (2018) Indocyanine green fluorescence angiography: a new ERAS item. Updat Surg 70: 427–432
- 27. De Nardi P, Elmore U, Maggi G et al (2020) Intraoperative angiography with indocyanine green to assess anastomosis perfusion in patients undergoing laparoscopic colorectal resection: results of a multicenter randomized controlled trial. Surg Endosc 34:53–60
- Dinallo AM, Kolarsick P, Boyan WP, Protyniak B, James A, Dressner RM, Arvanitis ML (2019) Does routine use of indocyanine green fluorescence angiography prevent anastomotic leaks? A retrospective cohort analysis. Am J Surg 218:136–139
- 29. Hasegawa H, Tsukada Y, Wakabayashi M, Nomura S, Sasaki T, Nishizawa Y, Ikeda K, Akimoto T, Ito M (2020) Impact of intraoperative indocyanine green fluorescence angiography on anastomotic leakage after laparoscopic sphincter-sparing surgery for malignant rectal tumors. Int J Color Dis 35:471–480
- 30. Impellizzeri HG, Pulvirenti A, Inama M et al (2020) Near-infrared fluorescence angiography for colorectal surgery is associated with a reduction of anastomotic leak rate. Updat Surg 72:991–998
- Ishii M, Hamabe A, Okita K, Nishidate T, Okuya K, Usui A, Akizuki E, Satoyoshi T, Takemasa I (2020) Efficacy of indocyanine green fluorescence angiography in preventing anastomotic leakage after laparoscopic colorectal cancer surgery. Int J Color Dis 35:269–275
- Jafari MD, Lee KH, Halabi WJ, Mills SD, Carmichael JC, Stamos MJ, Pigazzi A (2013) The use of indocyanine green fluorescence to assess anastomotic perfusion during robotic assisted laparoscopic rectal surgery. Surg Endosc 27:3003–3008
- Kim JC, Lee JL, Yoon YS, Alotaibi AM, Kim J (2016) Utility of indocyanine-green fluorescent imaging during robot-assisted sphincter-saving surgery on rectal cancer patients. Int J Med Robot 12:710–717
- Kin C, Vo H, Welton L, Welton M (2015) Equivocal effect of intraoperative fluorescence angiography on colorectal anastomotic leaks. Dis Colon Rectum 58:582–587
- Kudszus S, Roesel C, Schachtrupp A, Hoer JJ (2010) Intraoperative laser fluorescence angiography in colorectal surgery: a noninvasive analysis to reduce the rate of anastomotic leakage. Langenbeck's Arch Surg 395:1025–1030
- Mizrahi I, Abu-Gazala M, Rickles AS, Fernandez LM, Petrucci A, Wolf J, Sands DR, Wexner SD (2018) Indocyanine green fluorescence angiography during low anterior resection for low rectal cancer: results of a comparative cohort study. Tech Coloproctol 22: 535–540
- 37. Otero-Pineiro AM, de Lacy FB, Van Laarhoven JJ et al (2020) The impact of fluorescence angiography on anastomotic leak rate following transanal total mesorectal excision for rectal cancer: a comparative study. Surg Endosc
- Ris F, Liot E, Buchs NC, Kraus R, Ismael G, Belfontali V, Douissard J, Cunningham C, Lindsey I, Guy R, Jones O, George B, Morel P, Mortensen NJ, Hompes R, Cahill RA, the Near-

Infrared Anastomotic Perfusion Assessment Network VOIR (2018) Multicentre phase II trial of near-infrared imaging in elective colorectal surgery. Br J Surg 105:1359–1367

- Shapera E, Hsiung RW (2019) Assessment of anastomotic perfusion in left-sided robotic assisted colorectal resection by Indocyanine green fluorescence angiography. Minim Invasive Surg 2019:3267217
- 40. Skrovina M, Bencurik V, Martinek L, Machackova M, Bartos J, Andel P, Stepanova E, Bunakova M, Vomackova K (2020) The significance of intraoperative fluorescence angiography in miniinvasive low rectal resections. Wideochir Inne Tech Maloinwazyjne 15:43–48
- 41. Tsang YP, Leung LA, Lau CW, Tang CN (2020) Indocyanine green fluorescence angiography to evaluate anastomotic perfusion in colorectal surgery. Int J Color Dis 35:1133–1139
- 42. Wada T, Kawada K, Hoshino N, Inamoto S, Yoshitomi M, Hida K, Sakai Y (2019) The effects of intraoperative ICG fluorescence angiography in laparoscopic low anterior resection: a propensity score-matched study. Int J Clin Oncol 24:394–402
- 43. Watanabe J, Ishibe A, Suwa Y, Suwa H, Ota M, Kunisaki C, Endo I (2020) Indocyanine green fluorescence imaging to reduce the risk of anastomotic leakage in laparoscopic low anterior resection for rectal cancer: a propensity score-matched cohort study. Surg Endosc 34:202–208
- 44. Wojcik M, Doussot A, Manfredelli S, Duclos C, Paquette B, Turco C, Heyd B, Lakkis Z (2020) Intraoperative fluorescence angiography is reproducible and reduces the rate of anastomotic leak after colorectal resection for cancer: a prospective case-matched study. Color Dis 22:1263–1270
- 45. Kudszus S, Roesel C, Schachtrupp A, Hoeer JJ (2010) Intraoperative laser fluorescence angiography in colorectal surgery: a noninvasive analysis to reduce the rate of anastomotic leakage. Langenbecks Arch Surg 395:1025–1030
- 46. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibañes E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M (2009) The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 250:187–196

- 47. Ashraf SQ, Burns EM, Jani A, Altman S, Young JD, Cunningham C, Faiz O, Mortensen NJ (2013) The economic impact of anastomotic leakage after anterior resections in English NHS hospitals: are we adequately remunerating them? Color Dis 15:e190–e198
- Lu ZR, Rajendran N, Lynch AC, Heriot AG, Warrier SK (2016) Anastomotic leaks after restorative resections for rectal cancer compromise cancer outcomes and survival. Dis Colon Rectum 59:236– 244
- 49. Wang S, Liu J, Wang S, Zhao H, Ge S, Wang W (2017) Adverse effects of anastomotic leakage on local recurrence and survival after curative anterior resection for rectal Cancer: a systematic review and meta-analysis. World J Surg 41:277–284
- D'Urso A, Agnus V, Barberio M et al (2020) Computer-assisted quantification and visualization of bowel perfusion using fluorescence-based enhanced reality in left-sided colonic resections. Surg Endosc
- Hayami S, Matsuda K, Iwamoto H, Ueno M, Kawai M, Hirono S, Okada K, Miyazawa M, Tamura K, Mitani Y, Kitahata Y, Mizumoto Y, Yamaue H (2019) Visualization and quantification of anastomotic perfusion in colorectal surgery using near-infrared fluorescence. Tech Coloproctol 23:973–980
- Ishige F, Nabeya Y, Hoshino I, Takayama W, Chiba S, Arimitsu H, Iwatate Y, Yanagibashi H (2019) Quantitative assessment of the blood perfusion of the gastric conduit by Indocyanine green imaging. J Surg Res 234:303–310
- Lütken CD, Achiam MP, Svendsen MB et al (2020) Optimizing quantitative fluorescence angiography for visceral perfusion assessment. Surg Endosc 34:5223–5233
- Lütken CD, Achiam MP, Osterkamp J, Svendsen MB, Nerup N (2020) Quantification of fluorescence angiography: toward a reliable intraoperative assessment of tissue perfusion - a narrative review. Langenbeck's Arch Surg

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.